Page last updated: 2024-10-20

thiosulfates and Deafness, Transitory

thiosulfates has been researched along with Deafness, Transitory in 20 studies

Thiosulfates: Inorganic salts of thiosulfuric acid possessing the general formula R2S2O3.
thiosulfate(2-) : A divalent inorganic anion obtained by removal of both protons from thiosulfuric acid.

Research Excerpts

ExcerptRelevanceReference
"We randomly assigned children older than 1 month and younger than 18 years of age who had standard-risk hepatoblastoma (≤3 involved liver sectors, no metastatic disease, and an alpha-fetoprotein level of >100 ng per milliliter) to receive cisplatin alone (at a dose of 80 mg per square meter of body-surface area, administered over a period of 6 hours) or cisplatin plus sodium thiosulfate (at a dose of 20 g per square meter, administered intravenously over a 15-minute period, 6 hours after the discontinuation of cisplatin) for four preoperative and two postoperative courses."9.27Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. ( Ansari, M; Brichard, B; Brock, PR; Brugières, L; Capra, M; Childs, M; Covezzoli, A; Czauderna, P; Dall'Igna, P; Hiyama, E; Laithier, V; Maibach, R; Mateos, ME; Morland, B; Neuwelt, EA; Perilongo, G; Rajput, K; Rangaswami, AA; Rechnitzer, C; Roebuck, D; Ronghe, M; Skeen, J; Sullivan, MJ; Veal, GJ, 2018)
"Sodium thiosulfate is an antioxidant shown in preclinical studies in animals to prevent cisplatin-induced hearing loss with timed administration after cisplatin without compromising the antitumour efficacy of cisplatin."9.24Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. ( Bliss, B; Chen, L; Freyer, DR; Knight, K; Krailo, MD; Lange, B; Neuwelt, EA; Pollock, BH; Ramdas, J; Sung, L; Van Hoff, D; VanSoelen, ML; Villaluna, D; Wiernikowski, J, 2017)
"To determine safety, feasibility, and preliminary activity of transtympanic injection of sodium thiosulfate (STS) against cisplatin-induced hearing loss (CIHL)."5.41Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial. ( Balm, AJM; Beijnen, JH; Burgers, JA; de Boer, JP; de Weger, VA; Dreschler, WA; Duinkerken, CW; Hauptmann, M; Marchetti, S; Nuijen, B; Pluim, D; Rosing, H; Schellens, JHM; van der Molen, L; Zuur, CL, 2021)
"Sodium thiosulfate (STS) has been described as a protective agent against CDDP toxicity, but it also reduces CDDP's antitumoral cytotoxicity."5.32Local application of sodium thiosulfate prevents cisplatin-induced hearing loss in the guinea pig. ( Fetoni, A; Guitton, MJ; Lloyd Faulconbridge, RV; Puel, JL; Pujol, R; Wang, J, 2003)
"We randomly assigned children older than 1 month and younger than 18 years of age who had standard-risk hepatoblastoma (≤3 involved liver sectors, no metastatic disease, and an alpha-fetoprotein level of >100 ng per milliliter) to receive cisplatin alone (at a dose of 80 mg per square meter of body-surface area, administered over a period of 6 hours) or cisplatin plus sodium thiosulfate (at a dose of 20 g per square meter, administered intravenously over a 15-minute period, 6 hours after the discontinuation of cisplatin) for four preoperative and two postoperative courses."5.27Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. ( Ansari, M; Brichard, B; Brock, PR; Brugières, L; Capra, M; Childs, M; Covezzoli, A; Czauderna, P; Dall'Igna, P; Hiyama, E; Laithier, V; Maibach, R; Mateos, ME; Morland, B; Neuwelt, EA; Perilongo, G; Rajput, K; Rangaswami, AA; Rechnitzer, C; Roebuck, D; Ronghe, M; Skeen, J; Sullivan, MJ; Veal, GJ, 2018)
"Sodium thiosulfate is an antioxidant shown in preclinical studies in animals to prevent cisplatin-induced hearing loss with timed administration after cisplatin without compromising the antitumour efficacy of cisplatin."5.24Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. ( Bliss, B; Chen, L; Freyer, DR; Knight, K; Krailo, MD; Lange, B; Neuwelt, EA; Pollock, BH; Ramdas, J; Sung, L; Van Hoff, D; VanSoelen, ML; Villaluna, D; Wiernikowski, J, 2017)
" We aimed to compare the incidence of hearing loss between patients treated with intra-arterial high-dose cisplatin chemoradiation with sodium thiosulfate (CRT-IA) and intravenous high-dose cisplatin chemoradiation without sodium thiosulfate (CRT-IV)."5.12Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. ( Balm, AJ; Dreschler, WA; Hart, AA; Lansdaal, PE; Rasch, CR; Schornagel, JH; Simis, YJ; Zuur, CL, 2007)
" Ototoxicity and subsequent permanent hearing loss remain a serious dose-limiting side effect associated with cisplatin treatment."2.94Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients. ( Hu, QY; Keilty, J; Kropp, J; McCarthy, R; Ren, Y; Shi, F; Soglia, J; Viglietta, V; Weber, P; Wolff, H, 2020)
"Our trial suggests that STS deposited on the round window was safe for the middle and inner ears."2.90A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer. ( Bairati, I; Bussières, R; Côté, M; Guitton, MJ; Leclerc, M; Meyer, F; Philippon, D; Rolland, V, 2019)
"Despite ototoxicity being a prevalent consequence of cisplatin chemotherapy, little guidance exists on interventions to prevent this permanent and progressive adverse event."2.66Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline. ( Brock, PR; Cabral, S; Chang, KW; Dupuis, LL; Epelman, S; Freyer, DR; Knight, K; Mills, D; Phillips, R; Potter, E; Risby, D; Robinson, PD; Simpkin, P; Sullivan, M; Sung, L, 2020)
"The Children's Oncology Group (COG) Cancer Control and Supportive Care Neurotoxicity Subcommittee therefore conducted a survey of providers at COG institutions to determine perspectives on pediatric otoprotection practices and research surrounding three major themes: (1) prevalence of routine use of STS with cisplatin-based regimens, (2) application of audiometry to cisplatin therapy, and (3) preferred modalities for otoprotection research."1.56Assessment of provider perspectives on otoprotection research for children and adolescents: A Children's Oncology Group Cancer Control and Supportive Care Committee survey. ( Dvorak, CC; Esbenshade, AJ; Freyer, DR; Hardy, KK; Orgel, E; Thomas, SM; Ullrich, NJ, 2020)
"Sodium thiosulfate (STS) has been described as a protective agent against CDDP toxicity, but it also reduces CDDP's antitumoral cytotoxicity."1.32Local application of sodium thiosulfate prevents cisplatin-induced hearing loss in the guinea pig. ( Fetoni, A; Guitton, MJ; Lloyd Faulconbridge, RV; Puel, JL; Pujol, R; Wang, J, 2003)

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (25.00)29.6817
2010's8 (40.00)24.3611
2020's7 (35.00)2.80

Authors

AuthorsStudies
Orgel, E2
Villaluna, D2
Krailo, MD2
Esbenshade, A1
Sung, L4
Freyer, DR5
Brock, PR3
Chang, KW1
Dupuis, LL1
Epelman, S1
Knight, K2
Mills, D1
Phillips, R1
Potter, E1
Risby, D1
Simpkin, P1
Sullivan, M1
Cabral, S1
Robinson, PD1
Viglietta, V1
Shi, F1
Hu, QY1
Ren, Y1
Keilty, J1
Wolff, H1
McCarthy, R1
Kropp, J1
Weber, P1
Soglia, J1
Boyce, AM1
Gafni, RI1
Ferreira, CR1
Ullrich, NJ1
Hardy, KK1
Thomas, SM1
Dvorak, CC1
Esbenshade, AJ1
Harao, T1
Yamada, A1
Kinoshita, M1
Kamimura, S1
Moritake, H1
Duinkerken, CW1
de Weger, VA1
Dreschler, WA2
van der Molen, L1
Pluim, D1
Rosing, H1
Nuijen, B1
Hauptmann, M1
Beijnen, JH1
Balm, AJM1
de Boer, JP1
Burgers, JA1
Marchetti, S1
Schellens, JHM1
Zuur, CL2
Maibach, R2
Childs, M1
Rajput, K1
Roebuck, D1
Sullivan, MJ2
Laithier, V1
Ronghe, M1
Dall'Igna, P1
Hiyama, E1
Brichard, B1
Skeen, J1
Mateos, ME1
Capra, M1
Rangaswami, AA1
Ansari, M1
Rechnitzer, C1
Veal, GJ1
Covezzoli, A1
Brugières, L1
Perilongo, G1
Czauderna, P1
Morland, B1
Neuwelt, EA4
Killock, D1
Frazier, AL1
Rolland, V1
Meyer, F1
Guitton, MJ2
Bussières, R1
Philippon, D1
Bairati, I1
Leclerc, M1
Côté, M1
Ishikawa, E1
Sugimoto, H1
Hatano, M1
Nakanishi, Y1
Tsuji, A1
Endo, K1
Kondo, S1
Wakisaka, N1
Murono, S1
Ito, M1
Yoshizaki, T1
Chen, L1
Bliss, B1
Pollock, BH1
Ramdas, J1
Lange, B1
Van Hoff, D1
VanSoelen, ML1
Wiernikowski, J1
Berglin, CE1
Pierre, PV1
Bramer, T1
Edsman, K1
Ehrsson, H1
Eksborg, S1
Laurell, G1
Blakley, BW2
Cohen, JI1
Doolittle, ND1
Muldoon, LL1
Campbell, KC1
Dickey, DT1
Wang, J1
Lloyd Faulconbridge, RV1
Fetoni, A1
Pujol, R1
Puel, JL1
Viallet, NR1
Begleiter, A1
Leith, MK1
Simis, YJ1
Lansdaal, PE1
Hart, AA1
Schornagel, JH1
Rasch, CR1
Balm, AJ1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 3 Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy Incorporating a Randomized Assessment of Sodium Thiosulfate as Otoprotection for Children With Localized Disease, and Respons[NCT04478292]Phase 3330 participants (Anticipated)Interventional2021-03-01Recruiting
A Multi-centre Open-label Randomised Phase III Trial of the Efficacy of Sodium Thiosulphate in Reducing Ototoxicity in Patients Receiving Cisplatin Chemotherapy for Standard Risk Hepatoblastoma[NCT00652132]Phase 3116 participants (Actual)Interventional2007-12-15Completed
A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children[NCT00716976]Phase 3131 participants (Actual)Interventional2008-06-23Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Hearing Thresholds For Key Frequencies at 1000 hz

Mean change in hearing threshold (post-pre) at 1000 hz. (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin

InterventionDecibels (Mean)
STS Arm (Sodium Thiosulfate Treatment)-0.676
Observation Arm-0.319

Change in Hearing Thresholds For Key Frequencies at 2000 hz

Mean change in hearing threshold (post-pre) at 2000 hz (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin

InterventionDecibels (Mean)
STS Arm (Sodium Thiosulfate Treatment)-1.18
Observation Arm0.638

Change in Hearing Thresholds For Key Frequencies at 4000 hz

Mean change in hearing threshold (post-pre) at 4000 hz. (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin

InterventionDecibels (Mean)
STS Arm (Sodium Thiosulfate Treatment)1.05
Observation Arm9.58

Change in Hearing Thresholds For Key Frequencies at 500 hz

Mean change in hearing threshold (post-pre) at 500 hz. (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin

InterventionDecibels (Mean)
STS Arm (Sodium Thiosulfate Treatment)-1.45
Observation Arm-1.11

Change in Hearing Thresholds For Key Frequencies at 8000 hz

Mean change in hearing threshold (post-pre) at 8000 hz. (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin

InterventionDecibels (Mean)
STS Arm (Sodium Thiosulfate Treatment)9.73
Observation Arm17.0

Event-Free Survival (EFS)

Proportion of patients event free at 4 years following enrollment. See EFS outcome measure description. (NCT00716976)
Timeframe: 4 years after enrollment

InterventionPercentage probability (Number)
STS Arm (Sodium Thiosulfate Treatment)53.7
Observation Arm61.4

Incidence of Hearing Loss

Hearing loss defined by comparing hearing sensitivity at follow up evaluation relative to baseline measurements using ASHA criteria. (NCT00716976)
Timeframe: 4 weeks after last dose of cisplatin

InterventionPatients (Number)
STS Arm (Sodium Thiosulfate Treatment)14
Observation Arm31

Overall Survival (OS)

Proportion of patients alive free at 4 years following enrollment. See OS outcome measure description. (NCT00716976)
Timeframe: 4 Years after enrollment

InterventionPercentage probability (Number)
STS Arm (Sodium Thiosulfate Treatment)69.6
Observation Arm82.0

Reviews

2 reviews available for thiosulfates and Deafness, Transitory

ArticleYear
Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline.
    The Lancet. Child & adolescent health, 2020, Volume: 4, Issue:2

    Topics: Adolescent; Antineoplastic Agents; Child; Cisplatin; Female; Hearing Loss; Humans; Male; Neoplasms;

2020
Generalized Arterial Calcification of Infancy: New Insights, Controversies, and Approach to Management.
    Current osteoporosis reports, 2020, Volume: 18, Issue:3

    Topics: Adenosine Monophosphate; Bone Density Conservation Agents; Calcinosis; Cardiovascular Agents; Chelat

2020

Trials

6 trials available for thiosulfates and Deafness, Transitory

ArticleYear
Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients.
    Investigational new drugs, 2020, Volume: 38, Issue:5

    Topics: Adult; Antineoplastic Agents; Cisplatin; Double-Blind Method; Female; Healthy Volunteers; Hearing Lo

2020
Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial.
    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2021, 06-01, Volume: 42, Issue:5

    Topics: Adult; Antineoplastic Agents; Cisplatin; Hearing Loss; Humans; Thiosulfates

2021
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
    The New England journal of medicine, 2018, Jun-21, Volume: 378, Issue:25

    Topics: Adolescent; Child; Child, Preschool; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Foll

2018
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
    The New England journal of medicine, 2018, Jun-21, Volume: 378, Issue:25

    Topics: Adolescent; Child; Child, Preschool; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Foll

2018
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
    The New England journal of medicine, 2018, Jun-21, Volume: 378, Issue:25

    Topics: Adolescent; Child; Child, Preschool; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Foll

2018
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
    The New England journal of medicine, 2018, Jun-21, Volume: 378, Issue:25

    Topics: Adolescent; Child; Child, Preschool; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Foll

2018
A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer.
    Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale, 2019, Jan-16, Volume: 48, Issue:1

    Topics: Aged; Antineoplastic Agents; Antioxidants; Carcinoma, Squamous Cell; Cisplatin; Female; Head and Nec

2019
Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
    The Lancet. Oncology, 2017, Volume: 18, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Antioxidants; Child; Child, Preschool; Cisplatin; Drug Therapy, C

2017
Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
    The Lancet. Oncology, 2017, Volume: 18, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Antioxidants; Child; Child, Preschool; Cisplatin; Drug Therapy, C

2017
Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
    The Lancet. Oncology, 2017, Volume: 18, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Antioxidants; Child; Child, Preschool; Cisplatin; Drug Therapy, C

2017
Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
    The Lancet. Oncology, 2017, Volume: 18, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Antioxidants; Child; Child, Preschool; Cisplatin; Drug Therapy, C

2017
Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-20, Volume: 25, Issue:24

    Topics: Antineoplastic Agents; Auditory Threshold; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Th

2007

Other Studies

12 other studies available for thiosulfates and Deafness, Transitory

ArticleYear
Sodium thiosulfate for prevention of cisplatin-induced hearing loss: updated survival from ACCL0431.
    The Lancet. Oncology, 2022, Volume: 23, Issue:5

    Topics: Cisplatin; Hearing Loss; Humans; Thiosulfates

2022
Assessment of provider perspectives on otoprotection research for children and adolescents: A Children's Oncology Group Cancer Control and Supportive Care Committee survey.
    Pediatric blood & cancer, 2020, Volume: 67, Issue:11

    Topics: Adolescent; Antineoplastic Agents; Antioxidants; Child; Cisplatin; Follow-Up Studies; Hearing Loss;

2020
Prevention of cisplatin-induced hearing-loss by sodium thiosulfate in medulloblastoma.
    Pediatrics international : official journal of the Japan Pediatric Society, 2020, Volume: 62, Issue:10

    Topics: Antineoplastic Agents; Cerebellar Neoplasms; Cisplatin; Hearing Loss; Humans; Medulloblastoma; Thios

2020
Sodium thiosulfate halves the risk of cisplatin-induced hearing loss.
    Nature reviews. Clinical oncology, 2018, Volume: 15, Issue:9

    Topics: Cisplatin; Hearing Loss; Humans; Thiosulfates

2018
Sodium Thiosulfate and Cisplatin-Induced Hearing Loss.
    The New England journal of medicine, 2018, 09-20, Volume: 379, Issue:12

    Topics: Antineoplastic Agents; Cisplatin; Deafness; Hearing Loss; Humans; Thiosulfates

2018
Sodium Thiosulfate and Cisplatin-Induced Hearing Loss.
    The New England journal of medicine, 2018, 09-20, Volume: 379, Issue:12

    Topics: Antineoplastic Agents; Cisplatin; Deafness; Hearing Loss; Humans; Thiosulfates

2018
Protective effects of sodium thiosulfate for cisplatin-mediated ototoxicity in patients with head and neck cancer.
    Acta oto-laryngologica, 2015, Volume: 135, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chelating Agents; Chemorad

2015
Hepatoblastoma, cisplatin, and ototoxicity: good news on deaf ears.
    Cancer, 2009, Dec-15, Volume: 115, Issue:24

    Topics: Amifostine; Cisplatin; Clinical Trials as Topic; Hearing Loss; Hepatoblastoma; Humans; Infant; Inter

2009
Prevention of cisplatin-induced hearing loss by administration of a thiosulfate-containing gel to the middle ear in a guinea pig model.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:6

    Topics: Animals; Antineoplastic Agents; Cisplatin; Ear, Middle; Female; Gels; Guinea Pigs; Hair Cells, Audit

2011
Strategies for prevention of toxicity caused by platinum-based chemotherapy: review and summary of the annual meeting of the Blood-Brain Barrier Disruption Program, Gleneden Beach, Oregon, March 10, 2001.
    The Laryngoscope, 2002, Volume: 112, Issue:11

    Topics: Animals; Antineoplastic Agents; Antioxidants; Blood-Brain Barrier; Carboplatin; Cisplatin; Head and

2002
Local application of sodium thiosulfate prevents cisplatin-induced hearing loss in the guinea pig.
    Neuropharmacology, 2003, Volume: 45, Issue:3

    Topics: Action Potentials; Animals; Cell Death; Cisplatin; Cochlea; Cytochrome c Group; Female; Guinea Pigs;

2003
Effect of sodium thiosulphate and cis-diamminedichloroplatinum on FADU tumour cells in nude mice.
    The Journal of otolaryngology, 2005, Volume: 34, Issue:6

    Topics: Animals; Antineoplastic Agents; Antioxidants; Carcinoma, Squamous Cell; Cisplatin; Disease Models, A

2005